Karuna Therapeutics Stock Price, News & Analysis (NASDAQ:KRTX) $189.48 +4.13 (+2.23%) (As of 02:23 PM ET) Add Compare Share Share Today's Range$185.84▼$193.5750-Day Range$161.01▼$190.9452-Week Range$158.38▼$245.00Volume116,879 shsAverage Volume329,602 shsMarket Capitalization$7.15 billionP/E RatioN/ADividend YieldN/APrice Target$259.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Karuna Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside39.5% Upside$259.38 Price TargetShort InterestBearish5.06% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 5 Articles This WeekInsider TradingSelling Shares$5.27 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($11.31) to ($11.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector494th out of 949 stocksPharmaceutical Preparations Industry231st out of 437 stocks 4.4 Analyst's Opinion Consensus RatingKaruna Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $259.38, Karuna Therapeutics has a forecasted upside of 39.5% from its current price of $185.91.Amount of Analyst CoverageKaruna Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.06% of the outstanding shares of Karuna Therapeutics have been sold short.Short Interest Ratio / Days to CoverKaruna Therapeutics has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Karuna Therapeutics has recently increased by 3.80%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldKaruna Therapeutics does not currently pay a dividend.Dividend GrowthKaruna Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KRTX. Previous Next 3.3 News and Social Media Coverage News SentimentKaruna Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Karuna Therapeutics this week, compared to 4 articles on an average week.MarketBeat Follows1 people have added Karuna Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karuna Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,270,775.00 in company stock.Percentage Held by Insiders13.20% of the stock of Karuna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karuna Therapeutics are expected to grow in the coming year, from ($11.31) to ($11.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karuna Therapeutics is -17.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karuna Therapeutics is -17.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKaruna Therapeutics has a P/B Ratio of 5.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Karuna Therapeutics Stock (NASDAQ:KRTX)Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Read More KRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRTX Stock News HeadlinesNovember 29, 2023 | msn.comFDA accepts Karuna Therapeutics schizophrenia drug for reviewNovember 29, 2023 | markets.businessinsider.comFDA Accepts New Drug Application For Karuna Therapeutics' KarXT To Treat SchizophreniaNovember 29, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 29, 2023 | finance.yahoo.comKaruna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of SchizophreniaNovember 24, 2023 | benzinga.comKaruna Therapeutics Stock (NASDAQ:KRTX) Dividends: History, Yield and DatesNovember 21, 2023 | americanbankingnews.comKaruna Therapeutics' (KRTX) Buy Rating Reaffirmed at HC WainwrightNovember 21, 2023 | markets.businessinsider.comPositive Phase 1b Trial Results Bolster Buy Rating for Karuna Therapeutics: Potential for Rapid Market Adoption of KarXTNovember 21, 2023 | markets.businessinsider.comKaruna Therapeutics Stock Receives Buy Rating Following Successful Phase 1b ABPM Study Results of KarXTNovember 29, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 19, 2023 | americanbankingnews.comKaruna Therapeutics (NASDAQ:KRTX) Trading 5.7% Higher November 19, 2023 | americanbankingnews.comKaruna Therapeutics (NASDAQ:KRTX) Stock Rating Reaffirmed by WedbushNovember 19, 2023 | americanbankingnews.comKaruna Therapeutics (NASDAQ:KRTX) Rating Reiterated by JMP SecuritiesNovember 17, 2023 | msn.comKaruna Therapeutics Says Its Antipsychotic Candidate Shows Favorable Cardiovascular Safety Profile In Schizophrenia PatientsNovember 17, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Notable Labs (NTBL), Karuna Therapeutics (KRTX)November 17, 2023 | markets.businessinsider.comAnalyst Endorses Karuna Therapeutics’ KarXT Following Positive Safety Trial Results and Anticipates High Market PotentialNovember 17, 2023 | finance.yahoo.comKaruna (KRTX) Posts Upbeat Safety Data on Schizophrenia DrugNovember 16, 2023 | msn.comKaruna reports positive safety data for schizophrenia drug KarXTNovember 16, 2023 | finance.yahoo.comKaruna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in SchizophreniaNovember 6, 2023 | markets.businessinsider.comKaruna Therapeutics Earns ‘Buy’ Rating: Strong Clinical Progress and Robust Financial Position Bolster ConfidenceNovember 6, 2023 | finance.yahoo.comKaruna Therapeutics, Inc. (NASDAQ:KRTX) Q3 2023 Earnings Call TranscriptNovember 6, 2023 | seekingalpha.comKaruna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond DopamineNovember 5, 2023 | seekingalpha.comKaruna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call TranscriptNovember 4, 2023 | markets.businessinsider.comBuy Rating for Karuna Therapeutics: Promising Outlook Based on KarXT’s Potential and Ongoing Clinical ProgramsNovember 3, 2023 | finance.yahoo.comKaruna's (KRTX) Q3 Loss Wider-Than-Expected, Sales MissNovember 3, 2023 | finance.yahoo.comQ3 2023 Karuna Therapeutics Inc Earnings CallNovember 2, 2023 | finance.yahoo.comKaruna Therapeutics Inc (KRTX) Reports Q3 2023 Financial Results and Business UpdatesNovember 2, 2023 | finance.yahoo.comKaruna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business UpdatesSee More Headlines Receive KRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KRTX CUSIPN/A CIK1771917 Webkarunatx.com Phone(857) 449-2244FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$259.38 High Stock Price Target$318.00 Low Stock Price Target$209.00 Potential Upside/Downside+36.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($10.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-276,340,000.00 Net Margins-2,795.96% Pretax Margin-6,661.80% Return on Equity-29.58% Return on Assets-28.61% Debt Debt-to-Equity RatioN/A Current Ratio27.88 Quick Ratio27.88 Sales & Book Value Annual Sales$10.64 million Price / Sales676.41 Cash FlowN/A Price / Cash FlowN/A Book Value$35.05 per share Price / Book5.44Miscellaneous Outstanding Shares37,730,000Free Float32,747,000Market Cap$7.20 billion OptionableNot Optionable Beta1.14 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Andrew Craig Miller (Age 41)Co-Founder & COO Comp: $835.4kDr. Steven M. Paul M.D. (Age 72)President of Research and Development, Chief Scientific Officer & Director Comp: $1.32MDr. Stephen K. Brannan (Age 67)Chief Medical Officer Comp: $751.75kMr. William Meury (Age 55)President, CEO & Director Mr. Jason Parker BrownChief Financial OfficerMs. Alexis SmithVice President of Corporate Affairs & Investor RelationsMs. Mia Kelley J.D.Vice President of Legal AffairsMr. Frank TruslowSenior Vice President of Corporate DevelopmentMr. Jonathan RosinChief Human Resources OfficerDr. Alan BreierChair of Scientific Advisory Board & Chief Clinical AdvisorMore ExecutivesKey CompetitorsIonis PharmaceuticalsNASDAQ:IONSCatalentNYSE:CTLTJazz PharmaceuticalsNASDAQ:JAZZGrifolsNASDAQ:GRFSRoivant SciencesNASDAQ:ROIVView All CompetitorsInsiders & InstitutionsDeutsche Bank AGBought 7,282 shares on 11/24/2023Ownership: 0.137%Walleye Capital LLCSold 200 shares on 11/21/2023Ownership: 0.000%Walleye Trading LLCSold 2,700 shares on 11/21/2023Ownership: 0.000%Comerica BankBought 449 shares on 11/21/2023Ownership: 0.001%Public Employees Retirement System of OhioSold 1,604 shares on 11/16/2023Ownership: 0.038%View All Insider TransactionsView All Institutional Transactions KRTX Stock Analysis - Frequently Asked Questions Should I buy or sell Karuna Therapeutics stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KRTX shares. View KRTX analyst ratings or view top-rated stocks. What is Karuna Therapeutics' stock price target for 2024? 12 Wall Street analysts have issued 1-year price targets for Karuna Therapeutics' shares. Their KRTX share price targets range from $209.00 to $318.00. On average, they expect the company's share price to reach $259.38 in the next twelve months. This suggests a possible upside of 39.5% from the stock's current price. View analysts price targets for KRTX or view top-rated stocks among Wall Street analysts. How have KRTX shares performed in 2023? Karuna Therapeutics' stock was trading at $196.50 at the start of the year. Since then, KRTX stock has decreased by 5.4% and is now trading at $185.91. View the best growth stocks for 2023 here. When is Karuna Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our KRTX earnings forecast. How were Karuna Therapeutics' earnings last quarter? Karuna Therapeutics, Inc. (NASDAQ:KRTX) released its quarterly earnings data on Thursday, November, 2nd. The company reported ($3.16) EPS for the quarter, missing analysts' consensus estimates of ($2.74) by $0.42. Karuna Therapeutics had a negative trailing twelve-month return on equity of 29.58% and a negative net margin of 2,795.96%. What ETFs hold Karuna Therapeutics' stock? ETFs with the largest weight of Karuna Therapeutics (NASDAQ:KRTX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ) and Vanguard Russell 2000 Growth ETF (VTWG). What other stocks do shareholders of Karuna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS). When did Karuna Therapeutics IPO? (KRTX) raised $70 million in an IPO on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Karuna Therapeutics' major shareholders? Karuna Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (14.98%), Pivotal bioVenture Partners Investment Advisor LLC (2.11%), Rock Springs Capital Management LP (1.34%), Invesco Ltd. (0.97%), Eventide Asset Management LLC (0.90%) and Brown Advisory Inc. (0.86%). Insiders that own company stock include Andrew Craig Miller, Atul Pande, James Healy, Jeffrey M Jonas, Laurie J Olson, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi. View institutional ownership trends. How do I buy shares of Karuna Therapeutics? Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:KRTX) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karuna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.